Roche, Sequoia dips toes in AIDS patent pool: Abbott, BI, BMS, Merck, and Tibotec stay dry
This article was originally published in Scrip
Executive Summary
Four pharmaceutical companies – F. Hoffman-La Roche, Gilead Sciences, Sequoia Pharmaceuticals, and ViiV Healthcare – have "entered or are preparing to enter" into active negotiations with the AIDS medicines patent pool which wants their patent rights so generic firms can make affordable fixed-dose combination antiretrovirals for developing countries. But another five firms are not.